Skip to content

Immune Function of Infants With HIV

Killer Cells and Viral Load in Vertical HIV Infection

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT00073229
Enrollment
80
Registered
2003-11-19
Start date
2000-07-31
Completion date
2005-06-30
Last updated
2008-09-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

HIV Infections

Keywords

AIDS, Vertical Transmission, Acute Infection

Brief summary

This observational study will evaluate data from infants born to HIV infected mothers in order to better characterize disease progression in early HIV infection.

Detailed description

The role of HIV-specific cytotoxic T-lymphocytes (CTL) in controlling viremia and protecting against disease progression following vertical infection may be dependent upon CTL functional responses as well as on the timing of detection, magnitude, and breadth of the responses. Novel and sensitive assay systems (MHC-peptide tetramers, ELISPOT assays, intracellular cytokine assays) have enhanced the detection and characterization of virus-specific CTL responses in the peripheral blood. This study will use these novel methods to examine the timing of detection, magnitude, specificity, and in vitro functional properties of HIV-specific CTL in infants; to evaluate the effects of potent combination antiretroviral therapy on HIV-specific CTL in infants; and to evaluate the immunogenicity of recombinant pox-based vaccines in HIV infected infants with prolonged viral suppression following early potent combination antiretroviral therapy. Blood samples from infants born to HIV infected women will be obtained from infants enrolled in other HIV trials. Generally, samples will be obtained at birth, Week 1, and Months 1, 2, 4, 6, 9, and 12.

Interventions

None listed

Sponsors

National Institute of Allergy and Infectious Diseases (NIAID)
Lead SponsorNIH

Eligibility

Sex/Gender
ALL
Age
No minimum to 24 Months
Healthy volunteers
No

Inclusion criteria

* Infants and children born to HIV infected women

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026